Results 81 to 90 of about 14,237 (205)

Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL‐Fusion Leukemia

Cancer Science, EarlyView.
Combined SETD2 and menin inhibitors make synergistic effects against MLL‐fusion leukemia; the combination therapy reduces the expression of target genes through blocking transcription elongation and initiation. ABSTRACT During transcriptional elongation, the histone methyltransferase SETD2 binds to RNA polymerase II and deposits trimethylation marks at
Anpei Li, Yuan Zhang, Ziwei Li, Anhao Liu, Li Zhang, Shubin Gao, Xiao Lin, Xiaoming Liu, Huan Li, Guanghui Jin, Bin Xu   +10 more
wiley   +1 more source

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice [PDF]

Translational Psychiatry, 2017
AbstractHistone acetylation is essential for memory formation and its deregulation contributes to the pathogenesis of Alzheimer’s disease. Thus, targeting histone acetylation is discussed as a novel approach to treat dementia. The histone acetylation landscape is shaped by chromatin writer and eraser proteins, while readers link chromatin state to ...
Benito, E, Ramachandran, B, Schroeder, H, Schmidt, G, Urbanke, H, Burkhardt, S, Capece, V, Dean, C, Fischer, A   +8 more
openaire   +4 more sources

Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain‐Containing Proteins

ChemBioChem, Volume 27, Issue 13, 14 July 2026.
The function of bromodomain‐containing proteins in regulating gene transcription is reviewed here, including the development of chemical probes and targeted protein degradation modalities (e.g., PROTACs). This extends to clinical efforts targeting the BET bromodomain‐containing proteins. Challenges of selectivity, future prospects, and the differential
Cole R. Scholtz, William C. K. Pomerantz
wiley   +1 more source

AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells

, 2017
Purpose: Bromodomain and extraterminal domain (BET) inhibitors are promising epigenetic agents for the treatment of various subsets of acute myeloid leukemia (AML).
민유홍, 장지은, 이정연, 정준원, 김진석   +4 more
core   +1 more source

Multiple myeloma: A tale of deregulated transcription factors

HemaSphere, Volume 10, Issue 7, July 2026.
Abstract A comprehensive understanding of the molecular mechanisms underlying multiple myeloma (MM) pathogenesis is essential for developing therapeutic strategies that overcome disease heterogeneity and treatment relapse. In this review, we focus on transcription factors (TFs), key regulators of gene expression that play critical roles in normal ...
Nahia Gómez‐Echarte, Edurne San José‐Enériz, Estíbaliz Urizar‐Compains, Paula Rodriguez‐Otero, Felipe Prósper, Xabier Agirre   +5 more
wiley   +1 more source

Integrating Oncolytic Virus Engineering and Delivery Strategies for Enhanced Cancer Virotherapy

Aggregate, Volume 7, Issue 6, June 2026.
Integrated engineering strategies combining oncolytic virus (OV) design with advanced delivery platforms overcome biological barriers and enhance cancer virotherapy. Genetic engineering improves viral potency and selectivity, while local and systemic delivery systems promote viral protection, tumor targeting, penetration, and tumor microenvironment ...
Jiliang Zhao, Dong Wang, Lei Wang, Hongkai Zhang, Yue Sun, Dan Ding   +5 more
wiley   +1 more source

JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer

, 2016
Overexpression of c-Myc is associated with worse outcomes in endometrial cancer, indicating that c-Myc may be a promising target for endometrial cancer therapy.
Clark, Leslie H., Zhang, Lu, Zhou, Chunxiao, Guo, Hui, Li, Jing, Kilgore, Joshua E., Jackson, Amanda L., Qiu, Haifeng, Gehrig, Paola A., Bae-Jump, Victoria L.   +9 more
core   +1 more source

Bromodomain and extraterminal protein inhibitor JQ1 induces maturation arrest and disrupts the cytoplasmic organization in mouse oocytes under in vitro conditions

Scientific Reports
JQ1, a small cell-permeable molecule is known for its potent inhibitory action on bromodomain and extraterminal (BET) proteins. Although earlier studies have shown its inhibitory effect on male gametogenesis, limited information is available about its ...
Keerthana Karunakar Poojary, Jyolsna Ponnaratta Kunhiraman, Vanishree Vasave Madhvacharya, Sandhya Kumari, Navami Krishna, Suresh P S, Rajanikant G K, Srinivas Mutalik, Nadeem Khan Ghani, Shama Prasada Kabekkodu, Thottethodi Subrahmanya Keshava Prasad, Satish Kumar Adiga, Guruprasad Kalthur   +12 more
doaj   +1 more source

JQ1 increases BRD4 complex interaction with viral gene promoters.

, 2016
HeLa cell were infected with HSV-1 at 10 MOI in the absence or presence of 500 nM JQ1 for 6 hr. Protein association and their interaction with viral gene promoters were determined by immunoprecipitation, by immunostaining, and by ChIP assays ...
Ke Ren (34504), Yayi Hou (139450), Erguang Li (367297), Xiaoqing Chen (89898), Wei Zhang (405), Yue Dai (287672), Ren Xiang Tan (1633183), Yingyu Ma (3229974), Yimei Fan (615439)   +8 more
core   +1 more source

Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells

, 2023
Background: Bromodomain and extra-terminal (BET) proteins are recognized acetylated lysine of histone 4 and act as scaffolds to recruit many other proteins to promoters and enhancers of active genes, especially at the super-enhancers of key genes ...
Jami, Mohammad-Saeid, Soltani, Amin, Heshmati, Masoud, Hedayatollah Shirzad, Atefeh Sharifhoseini, Shirzad, Hedayatollah, Babri A. Judd, Entezam, Mahshad, Judd, Babri A., Ghatrehsamani, Mahdi, Amin Soltani, Mahshad Entezam, Mahdi Ghatrehsamani, Mohammad-Saeid Jami, Masoud Heshmati, Morteza Sedehi, Sharifhoseini, Atefeh, Sedehi, Morteza   +17 more
core   +1 more source